Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Jul 30, 2026 | $0.64 | +42.2% | $1.31B | +13.1% | $0.61 |
| Q1 FY26ended Mar 31, 2026 | May 7, 2026 | $0.51 | +88.9% | $1.19B | +15.0% | $0.47 |
| Q4 FY25ended Dec 31, 2025 | — | $0.67 | +81.1% | $1.26B | +13.1% | — |
| Q3 FY25ended Sep 30, 2025 | — | $0.70 | +105.9% | $1.21B | +21.6% | — |
| Q2 FY25ended Jun 30, 2025 | — | $0.45 | +28.6% | $1.16B | +15.2% | — |
| Q1 FY25ended Mar 31, 2025 | — | $0.27 | −25.0% | $1.04B | +12.5% | — |
| Q4 FY24ended Dec 31, 2024 | — | $0.37 | −38.3% | $1.11B | +7.6% | — |
| Q3 FY24ended Sep 30, 2024 | — | $0.34 | +17.2% | $994.20M | +2.0% |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe DexCom shares, not any token. As of Jul 30, 2026, from Massive's standardised financials and the earnings calendar.
| — |
| Q2 FY24ended Jun 30, 2024 | — | $0.35 | — | $1.00B | — | — |
| Q1 FY24ended Mar 31, 2024 | — | $0.36 | — | $921.00M | — | — |
| Q4 FY23ended Dec 31, 2023 | — | $0.60 | — | $1.03B | — | — |
| Q3 FY23ended Sep 30, 2023 | — | $0.29 | — | $975.00M | — | — |